Active substance
Pimozide
- SFDA 1
- US FDA 3
- Health Canada 2
- US price lines 2
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ORAP FORTE TAB 4 MG | 4 mg | Tablet · Oral use | 20 Blister | SAR 27.95 | NCE · Prescription | JANSSEN PHARMACEUTICA N.V | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PIMOZIDE | 1MG; 2MG | tablet · oral | PH HEALTH | Prescription | 28 Sep 2015 |
| PIMOZIDE | 1MG; 2MG | tablet · oral | NOVITIUM PHARMA | Prescription | 13 Apr 2026 |
| ORAP | 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | TEVA | Discontinued | 31 Jul 1984 |
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PIMOZIDE 1 MG TABLET | $1.23492 | per EA | 23 Sep 2026 |
| US NADAC | PIMOZIDE 2 MG TABLET | $1.63995 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Pimozide 4mg tablets | £40.31 | 100 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.